BALTIMORE (Stockpickr) -- The S&P 500 has had a blockbuster year so far in 2013. At last count, shares of the big index have rocketed 23% higher since the start of the calendar year. So if you're not thinking defensively right now, you could be in for a rude awakening.
>>5 Stocks Poised for Breakouts
In football, the saying goes: The best defense is a good offense. That might be good advice for Super Bowl contenders, but it's terrible advice for investors.
As an investor, the best defense is a, well, good defense. And the best offense is a good defense too.
That's not just some investing platitude. It's backed up by stock market research. According to data collected by Cambria Investment Management CIO Mebane Faber, missing the best and worst days of the year with a defensive market posture actually outperforms a buy-and-hold approach.
So today, we're going defensive with five "sin stocks."
>>Do You Own These Blue-Chips? Sell Them!
Kohl?s Corporation operates department stores in the United States. The company?s stores offer private and exclusive, as well as national branded apparel, footwear, and accessories for women, men, and children; soft home products, such as sheets and pillows; and housewares primarily to middle-income customers. As of January 29, 2011, it operated 1,089 stores in 49 states. The company also offers on-line shopping on its Web site at Kohls.com. Kohl?s Corporation was founded in 1962 and is headquartered in Menomonee Falls, Wisconsin.
Advisors' Opinion: - [By Traders Reserve]
These customers are going to spend less at Kohl�� (KSS) and Target (TGT) and low-income customers are going to break Wal-Mart�� (WMT) heart�(Well, given how they pay their employees, it�� won�� be a broken heart, it will be a broken holiday season).
- [By Ben Levisohn]
Consumer stocks got a boost from the deal today, with three among the top-15 gainers in the S&P 500.�JC Penney (JCP) rose 4.2% to $7.47, TJX Companies (TJX) jumped 3.8% to $57.72 and Kohl’s (KSS) advanced 3.5% to $53.24
- [By Varun Chandan, Arora]
This has been an excellent year for most department stores. Year-to-date, shares of Macy's (NYSE: M ) have gained nearly 43%, while�Kohl's (NYSE: KSS ) has gained nearly 30%. One notable, but not surprising, exception has been J.C. Penney (NYSE: JCP ) . Shares of the Plano, Texas-based company have fallen more than 55% this year as the company has continued to struggle. However, last month the company reported encouraging quarterly results which indicate that its turnaround plan is working. So, is this a good time to buy J.C. Penney?
10 Best Defensive Stocks To Own For 2014: Westar Energy Inc.(WR)
Westar Energy, Inc., an electric utility company, engages in the generation, transmission, and distribution of electricity. It produces electricity through various sources, including coal, wind, nuclear, natural gas, oil, and diesel. As of October 26, 2011, it served approximately 687,000 residential, commercial, and industrial customers in Kansas; and had approximately 7,100 megawatts of generating capacity, as well as operated and coordinated approximately 34,000 miles of electric distribution and transmission lines. Westar Energy, Inc. also engages in energy marketing, and in the purchase and sale of electricity. It serves public streets, highways, electric cooperatives, municipalities, and other electric utilities in central and northeastern Kansas, including the cities of Topeka, Lawrence, Manhattan, Salina, and Hutchinson. The company was founded in 1924 and is headquartered in Topeka, Kansas.
Advisors' Opinion: - [By Brian Pacampara]
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, electric utility Westar Energy (NYSE: WR ) has earned a respected four-star ranking.
- [By Ben Levisohn]
Now don’t misunderstand. Gordon isn’t telling investors to avoid all regulated utilities. He has some favorites, including American Electric Power (AEP), Dominion Resources (D), ITC Holdings (ITC), Pinnacle West Capital (PNW) and Westar Energy (WR).
10 Best Defensive Stocks To Own For 2014: Delphi Automotive PLC (DLPH)
Delphi Automotive PLC (Delphi), incorporated on May 19, 2011, is a global vehicle components manufacturer and provides electrical and electronic, powertrain, safety and thermal technology solutions to the global automotive and commercial vehicle markets. As of December 31, 2012, the Company operated 126 manufacturing facilities and 15 technical centers utilizing a regional service model that enables it to serve its global customers. The Company operates through four segments: Electrical / Electronic Architecture; Powertrain Systems; Electronics and Safety and Thermal Systems. In October 2012, the Company acquired FCI Group�� Motorized Vehicles Division.
The Company�� Electrical / Electronic Architecture segment provides complete design of the vehicle�� electrical architecture, including connectors, wiring assemblies and harnesses, electrical centers and hybrid power distribution systems. Its Powertrain Systems segment provides systems integration of full end-to-end gasoline and diesel engine management systems, including fuel handling, fuel injection, combustion, electronic controls and test and validation capabilities. Its Electronics and Safety segment provides critical components, systems and advanced software for passenger safety, security, comfort and infotainment, as well as vehicle operation, including body controls, reception systems, infotainment and connectivity systems, hybrid vehicle power electronics, passive and active safety electronics, displays and mechatronics. Thermal Systems segment provides powertrain cooling and heating, ventilating and air conditioning (HVAC) systems, such as compressors, systems and controls, and heat exchangers for the vehicle markets.
Electrical/Electronic Architecture
The Company�� offers complete electrical/electronic architectures for its customer-specific needs. Connectors are engineered for use in the automotive and related markets, but also have applications in the aerospace, military and telematics sector! s. Electrical centers provide centralized electrical power and signal distribution and all of the associated circuit protection and switching devices, thereby optimizing the overall vehicle electrical system. Distribution systems are integrated into one optimized vehicle electrical system, which can utilize smaller cable and gauge sizes and ultra-thin wall insulation.
The Company competes with Lear Corporation, Leoni AG, Molex Inc, TE Connectivity, Ltd., Sumitomo Corporation and Yazaki Corporation.
Powertrain Systems
The Company offers products for complete engine management systems (EMS) and other products to help optimize performance, emissions and fuel economy. The gasoline EMS portfolio features fuel injection and air/fuel control, valvetrain, ignition, sensors and actuators, transmission control products, and powertrain electronic control modules with software, algorithms and calibration. The diesel EMS product line offers common rail fuel and air injection system technologies. The Powertrain Systems segment also supplies integrated fuel handling systems for gasoline, diesel, flexfuel and biofuel configurations. It also includes diesel and automotive aftermarket and original equipment service in the Powertrain Systems segment.
The Company competes with BorgWarner Inc., Bosch Group, Continental AG, Denso Corporation, Hitachi, Ltd. and Magneti Marelli S.p.A.
Electronics and Safety
The Company offers a range of electronic and safety equipment in the areas of controls, security, infotainment, communications, safety systems and power electronics. Electronic controls products consist of body computers and security systems. Infotainment and driver interface portfolio consists of receivers, advanced reception systems, digital receivers, satellite audio receivers, navigation systems, displays and mechatronics. Safety electronics includes occupant detection systems, collision warning systems, advanced cruise control technologies a! nd collis! ion sensing. Electric and hybrid electric vehicle power electronics includes power modules, inverters and converters and battery packs.
The Company competes Autoliv AB, Bosch Group, Continental AG, Denso Corporation, Harman International Industries and Panasonic Corporation.
Thermal Systems
The Company offers energy efficient thermal system and component solutions for the automotive market and continues to develop applications for the non-automotive market. Its automotive thermal products are designed to meet customers��needs for powertrain thermal management and cabin thermal comfort. Powertrain cooling products include condenser, radiator, fan module and charge air cooling heat exchangers assemblies. Climate control portfolio includes HVAC modules, with evaporator and heater core components, compressors and controls.
The Company competes with Denso Corporation, MAHLE Behr Industry, Sanden Corporation, Valeo Inc. and Visteon Corporation.
Advisors' Opinion: - [By Patricio Kehoe]
As the U.S. automobile industry recovers, auto parts suppliers are expecting to see increasing sales volumes. Particularly firms such as Delphi Automotive (DLPH) and Stoneridge Inc. (SRI), which specialize in electronic components, expect to make large profits. Increasingly electrified vehicles, higher demand for hybrid and electric powertrain vehicles and stricter governmental emissions regulations should drive revenue growth for these firms in coming years.
- [By Ben Levisohn]
In our view, Lear�� valuation remains appealing for two core reasons: (1) Lear sports structurally�lower capex/sales vs. peers (< 3% vs. ~4+% for peers). That means that for a given EBITDA multiple, Lear will generate higher unlevered FCF than its peers, all else equal. Our 6.0x ��4E EBITDA target multiple = ~8% unlevered FCF yield, including restructuring. That Lear�� revenue is outpacing the industry while margins are expanding is evidence that capex is appropriately sized. We estimate Lear�� ��4 unlevered FCF yield is comfortably above peer average; (2) Lear�� EPMS segment appears to have crossed the threshold to becoming a double-digit EBITDA margin earner with clear secular growth attributes. We think a 7.5x EBITDA multiple is appropriate based on public peers (Delphi (DLPH)) and past connector M&A.�
- [By Ben Levisohn]
Morgan Stanley’s strategists are no fans of consumer sectors–staples or discretionary–but that doesn’t mean all consumers stocks are stinkers, as stocks like Delphi Automotive (DLPH) and Macy’s (M) look primed to shine.
10 Best Defensive Stocks To Own For 2014: Roche Holding AG (RHHBY)
Roche Holding AG is a Switzerland-based pharmaceuticals and diagnostics company. The Company belongs to the Roche Group that operates through numerous subsidiaries and associated companies located around the world. The Company�� products and services cover every stage of the healthcare process, from identifying disease susceptibilities and testing for disease in at-risk populations to prevention, diagnosis, therapy and treatment monitoring. Roche operates through two divisions: Pharmaceuticals and Diagnostics. Within the Pharmaceuticals Division there are three sub-divisions: Roche Pharmaceuticals, Genentech and Chugai. The Company�� Diagnostics Division includes five sub-divisions: Applied Science, Diabetes Care, Molecular Diagnostics, Tissue Diagnosis and Professional Diagnostics. Its activities are structured into six geographical segments: North America; Asia-Pacific; Western Europe; Latin America; Central and Eastern Europe, Middle East and Africa (CEMAI), and Japan. In March 2009, the Company completed the acquisition of Genentech, Inc. In March 2010, the Company acquired assets from BioMicro Systems for all products associated with the Roche NimbleGen microarray workflow.
During the year ended December 31, 2008, the Company Pharmaceuticals Division marketing gained approvals for its rheumatoid arthritis medicine Actemra/RoActemra in Japan, Switzerland and the European Union. In 2008, the division initiated 12 new phase III projects in, including clinical trials of the compounds pertuzumab, for breast cancer; taspoglutide, for type two diabetes, and dalcetrapib, for cardiovascular risk reduction. As of December 31, 2008, the Pharmaceuticals Division filed 11 major new marketing applications and gained 13 major regulatory approvals. At the beginning of 2009, the division�� research and development pipeline comprised 120 clinical projects, including 62 new molecular entities (NMEs) and 58 additional indications. Forty NMEs are in phase I, 16 in phase II and six in phase III or f! iled for regulatory review.
In 2008, Roche Pharmaceuticals signed a total of 57 new agreements including seven product transactions and 43 research and technology collaborations. In May 2008, Roche acquired Piramed Limited, a UK company with therapeutic research programmes targeting the PI3-kinase pathway in oncology and inflammatory disease. In June 2008, signed licensing agreement with ThromboGenics and BioInvent for their jointly developed anticancer agent TB-403 (R7334). In September, 2008, the Company acquired Mirus Bio Corporation active in the field of ribonucleic acid interference (RNAi) delivery and completed the acquisition of ARIUS Research Inc., which has a antibody platform that identifies and selects antibodies based on their functional ability to affect disease. S Research Inc. In January 2009, Roche acquired Memory Pharmaceuticals, which develops drug candidates for the treatment of debilitating central nervous system disorders such as Alzheimer�� disease and schizophrenia.
Pharmaceuticals
Within Pharmaceuticals division, the Company is engaged in the provision of drugs the areas of oncology, anemia, cardiovascular diseases, central nervous system, infectious diseases, inflammatory and autoimmune diseases, metabolic disorders, cancer, transplantation and virology. The products offered by Roche�� Pharmaceuticals division include MabThera/Rituxan, Herceptin, Avastin, Tamiflu, CellCept, NeoRecormon, Epogin, Pegasys, Tarceva, Xeloda, Bonviva, Boniva, Lucentis, Tamiflu, Xolair, Valcyte, Cymevene, Xenical, Pulmozyme, Nutropin, Neutrogin, Rocephin, Activase, TNKase and Madopar. The products offered by the Pharmaceuticals division are sold in seven geographic regions: North America; Asia-Pacific; Western Europe; Latin America; Central and Eastern Europe, Middle East and Africa (CEMAI), and Japan.
Diagnostics
Roche�� Diagnostics Division is a supplier of in vitro diagnostics (IVDs). Its products are used to test body fluids a! nd tissue! samples to obtain information for the purpose of preventing, diagnosing, treating and monitoring disease. The Company has business areas five within the diagnostics division: Professional Diagnostics, Diabetes Care, Tissue Diagnostics, Molecular Diagnostics and Applied Science. Roche�� Diagnostics division provides IVD services, including centralized laboratory testing and point-of-care diagnostics to molecular diagnostics and diabetes self management. In addition, it supplies research tools to life scientists.
Roche Professional Diagnostics supplies instrument systems, tests, software and services. It provides point-of-care testing products to support clinical decision-making close to the patient, in doctors��offices, emergency rooms and other primary and specialty care settings. Twelve Serum Work Area assays were rolled out during the year ended December 31, 2008, across Europe and in other markets. New assays included the Elecsys anti-TSH receptor antibody assay for the diagnosis of Graves��disease the Elecsys anti-CCP antibody assay, a test to aid the diagnosis of rheumatoid arthritis, and the Roche Cystatin C clinical chemistry test for early detection of impaired kidney function, among others. Roche Diabetes Care�� products portfolio covers the entire diabetes self-management spectrum, from glucose monitoring to insulin delivery, as well as monitoring systems with integrated lancets and test strips software for storing and analyzing data. Roche Tissue Diagnostics develops and manufactures medical diagnostic instruments and reagent systems that provide automation technology for use in the diagnosis and prognosis of cancer and infectious disease. In 2008 Roche Tissue Diagnostics launched ofhe Bench- Mark Ultra, a system that performs immunohistochemistry and in situ hybridisation testing simultaneously on a single continuous and random access platform. Roche Molecular Diagnostics develops and commercializes diagnostic and blood screening platforms and tests based on Roche�� ! real-time! polymerase chain reaction (PCR) technology. Applied Science business area supplies a specific reagents and test kits for use in life sciences encompassing biology, biotechnology ,medical research, as well as disease areas like cancer and virology. Applied Science�� business area product portfolio includes such sequencing systems as LightCycler 480, LightCycler 480 II, GS FLX Titanium. In addition, Applied Science offers xCELLigence cell analyzer.
Advisors' Opinion: - [By Maxx Chatsko]
Anytime a megablockbuster nears the end of its IP-protected life, plenty of companies will emerge to get a piece of the pie. In this case,�Roche� (NASDAQOTH: RHHBY ) has two megablockbusters with a combined $13.5 billion in 2012 sales coming off patent in the next several years. That is bad news for the innovator, but opens a big opportunity for the various companies targeting biosimilars. In fact, a total of 19 trials are under way to develop generic versions of Rituxan and Herceptin. In the following video, Fool contributor Maxx Chatsko tells investors which companies to keep an eye on in the race to unseat Roche.
- [By Ben Levisohn]
Shares of InterMune (ITMN) have jumped 36% to $73.40�after�Roche�(RHHBY) said it would buy the drug maker for $8.3 billion.
Burger King Worldwide�(BKW) has climbed 7.9% to $29.25�on reports that the hamburger joint is considering the purchase of Canadian coffee-outlet Tim Hortons�(THI) for the tax benefits. Tim Hortons has gained 15% to $72.00.
- [By Kanak Kanti, De]
Last week, Israel-based Teva Pharmaceuticals' (NYSE: TEVA ) generic product portfolio received a major boost after the Food and Drug Administration approved the company's generic version of Xeloda, a cancer drug. Roche's (NASDAQOTH: RHHBY ) Xeloda is an orally administered chemotherapy treatment for colorectal and breast cancers that have metastasized. Given the fact that Xeloda generated $1.6 billion in sales for Roche in 2012, Teva's generic version has significant potential.
- [By Bryan Murphy]
When most investors think of cancer stocks, names like Amgen, Inc. (NASDAQ:AMGN) or Roche Holding Ltd. (OTCMKTS:RHHBY) come to mind. And to be fair, they're both top-of-mind names for good reasons. Five of the world's top-ten selling cancer drugs are from Roche Holding, and Amgen is the world's biggest biotech company; it just spent $10 billion on the acquisition of an entire company almost to add just one cancer therapy to its library. Thing is, while Roche Holding Ltd. and Amgen, Inc. make top-notch drugs to treat cancer once acquired, neither actually does anything to prevent the development of cancer through metastasization. Indeed, the prevention of the spread of cancer isn't on the biopharma industry's radar at all, save one company - a little outfit called MetaStat Inc. (OTCBB:MTST).
10 Best Defensive Stocks To Own For 2014: The Charles Schwab Corporation(SCHW)
The Charles Schwab Corporation, through its subsidiaries, provides securities brokerage, banking, and related financial services to individuals and institutional clients. It offers various brokerage products and services comprising brokerage accounts with check-writing features, debit card, and billpay; individual retirement accounts; retirement plans for small to large businesses; college savings accounts; designated brokerage accounts; equity incentive plan accounts; and margin loans, as well as access to fixed income securities, equity and debt offerings, options, and futures. The company also provides various banking products and services, including checking accounts linked to brokerage accounts, savings accounts, certificates of deposit, demand deposit accounts, first mortgages, home equity lines of credit, and personal loans collateralized by securities. In addition, it offers trust custody services, personal trust reporting services, and administrative trustee servi ces; advisory services comprising separately managed accounts, customized personal advice for tailored portfolios, and planning and portfolio management; and third-party mutual funds, such as no-load mutual funds, proprietary mutual funds, and other third-party mutual funds, as well as mutual fund trading and clearing services to broker dealers. Further, the company offers third-party and proprietary exchange-traded funds; research, analytic tools, performance reports, market analysis, and educational materials; custodial, trading, technology, practice management, trust asset, and other support services to independent investment advisors; and retirement plan recordkeeping and related services, retirement plan trust and custody services, specialty brokerage services, and mutual fund clearing services. It operates primarily in the United States, the United Kingdom, and Hong Kong. The company was founded in 1971 and is headquartered in San Francisco, California.
Advisors' Opinion: 10 Best Defensive Stocks To Own For 2014: Cardinal Health Inc. (CAH)
Cardinal Health, Inc. operates as a healthcare solutions company that provides health care products and services. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, over-the-counter healthcare, specialty pharmaceutical, and consumer products to retail customers, hospitals, and alternate care providers in the United States and Puerto Rico. This segment also operates nuclear pharmacies and cyclotron facilities that prepare and deliver radiopharmaceuticals for use in nuclear imaging and other procedures in hospitals and clinics; offers third-party logistics support services; franchises retail pharmacies under the Medicine Shoppe and Medicap brands; and provides pharmacy and pharmaceutical repackaging services, as well as other services comprising distribution, inventory management, data/reporting, new product launch support, and contract and chargeback administration. The Medical segment distributes a range of medical, surgical, and laboratory products to hospitals, surgery centers, laboratories, physician offices, and other healthcare providers. This segment also develops, manufactures, and sources medical and surgical products, including sterile and non-sterile procedure kits; single-use surgical drapes, gowns, and apparel; exam and surgical gloves; and fluid suction and collection systems. Its medical and surgical products are sold directly or through third-party distributors in the United States, Canada, Europe, South America, and the Asia/Pacific region. The company was founded in 1979 and is headquartered in Dublin, Ohio.
Advisors' Opinion: - [By Victor Selva]
The company has a very attractive current ratio of 33.03% which is higher than its comps: Becton Dickinson & Co (BDX), Cardinal Health Inc (CAH), Cooper Companies (COO) and Luxottica Group S.p.A. (LUX).
- [By Keith Speights]
This market reaction doesn't mean that Lymphoseek lacks solid potential. It does. The product should appeal to oncologists. Navidea has a tight relationship with Cardinal Health (NYSE: CAH ) , which has exclusive U.S. distribution rights for Lymphoseek. Cardinal operates the largest nuclear pharmacy network in the nation with 140 pharmacies.
- [By Dividends4Life]
Linked here is a detailed quantitative analysis of Cardinal Health, Inc. (CAH). Below are some highlights from the above linked analysis:
Company Description: Cardinal Health Inc. is one of the leading wholesale distributors of pharmaceuticals, medical/surgical supplies and related products to a broad range of health care customers.
- [By Chad Fraser]
Big Moves Are Reshaping Baxter
Baxter shares have risen 6.8% year-to-date, below the S&P 500�� 7.6% gain. But even though the stock hasn�� caused a lot of buzz with investors, management has made a number of important moves in the past two years.
The first came in late 2012, when the company acquired Gambro AB for US$4.0 billion, marking the biggest acquisition in its 83-year history. Sweden-based Gambro makes dialysis products for patients with acute and chronic kidney disease. The company is the world�� second-largest manufacturer of dialysis machines, after Germany�� Fresenius.
Baxter already had a presence in the dialysis market but mainly focused on in-home equipment, while Gambro�� products are mostly used in clinics.
This is a large and growing market for the company: according to the Baxter, approximately two million people worldwide are on some form of dialysis, and that number is growing by more than 5% annually due to rising rates of diabetes and hypertension.
Another major move came in March, when Baxter announced that it would break itself into two separate firms along the lines of its current divisions; it aims to complete the split in mid-2015.
��he breakup makes sense because the two units have separate profiles, with the medical devices business being more defensive, while the biopharmaceuticals unit grows faster, albeit with greater risk,��wrote Springer.
One of those risks is rising competition. For example, Biogen Idec�� (NasdaqGS: BIIB) Eloctate hemophilia A therapy received FDA approval in June. Eloctate could become a significant competitor to Baxter�� Advate treatment, which controls about 35% of the market. But Advate has the advantage of being well established: it was approved more than a decade ago and is now used in 64 countries.
Eloctate is expected to cost roughly the same as Advate, but it requires fewer injections. Baxter is currently developing a longer-
10 Best Defensive Stocks To Own For 2014: Magnum Hunter Resources Corp (MHR)
Magnum Hunter Resources Corporation (Magnum Hunter), incorporated in June 1997, is an independent oil and gas company engaged in the exploration for and the exploitation, acquisition, development and production of crude oil, natural gas and natural gas liquids, primarily in the states of West Virginia, Ohio, Texas, Kentucky and North Dakota and in Saskatchewan, Canada. The Company is also engaged in midstream operations, including the gathering of natural gas through its ownership and operation of a gas gathering system in West Virginia and Ohio, named as its Eureka Hunter Pipeline System. The Company�� portfolio includes Marcellus/Utica Shales in West Virginia and Ohio, the Eagle Ford Shale in south Texas, and the Williston Basin/Bakken Shale in North Dakota and Saskatchewan, Canada. As of December 31, 2011, its proved reserves were 44.9 million barrels of oil equivalent and were approximately 48% oil. In August 2012, the Company closed on the acquisition of 1,885 net mineral acres located in Atascosa County, Texas. With this acquisition, the Company has approximately 7,278 gross acres and 5,212 net acres located in Atascosa County, Texas.
On May 3, 2011, it acquired NuLoch Resources Inc. In April 2011, Triad Hunter, its wholly owned subsidiary, acquired certain Marcellus Shale oil and gas properties located in Wetzel County, West Virginia. On April 13, 2011, it acquired NGAS Resources, Inc. In February 2012, Triad Hunter acquired leasehold mineral interests located primarily in Noble County, Ohio.
Eagle Ford Shale Properties
Eagle Ford Shale is located in Gonzales, Lavaca, Atascosa and Fayette Counties, Texas. The Eagle Ford Shale properties are held primarily by its wholly owned subsidiary, Eagle Ford Hunter, Inc. As of February 27, 2012, the Company�� Eagle Ford Shale properties included approximately 54,000 gross (24,000 net) acres primarily targeting the Eagle Ford Shale oil window, principally in Gonzales and Lavaca Counties, Texas. As of December 31! , 2011, proved reserves attributable to the Eagle Ford Shale properties were 5.4 million barrels of oil equivalent, of which 94% were oil and 24% were classified as proved developed producing, and 5.4 million barrels of oil equivalent. As of February 27, 2012, its Eagle Ford Shale properties included 18 gross (10 net) productive wells, of which it operated 14.
Williston Basin Properties
The Williston Basin is spread across North Dakota, Montana and parts of southern Canada. The basin produces oil and natural gas from a range of producing horizons, including the Madison, Bakken, Three Forks/Sanish and Red River formations. As of February 27, 2012, the Company�� Williston Basin properties included approximately 413,003 gross (122,561 net) acres. As of December 31, 2011, proved reserves attributable to the Williston Basin properties were 8.9 million barrels of oil equivalent, of which 94% were oil and 42% were classified as proved developed producing, and 8.8 million barrels of oil equivalent. As of February 27, 2012, the Williston Basin properties included approximately 288 gross (98.9 net) productive wells.
The Williston Hunter United States property acreage is located in Divide and Burke Counties, North Dakota, with its primary production from the Bakken Shale and Three Forks/Sanish formations. As of February 27, 2012, its Williston Hunter United States properties included approximately 36,355 net acres in the Williston Basin in North Dakota. As of February 27, 2012, the Williston Hunter United States properties included approximately 105 gross (9.5 net) productive wells. The Company�� Williston Hunter Canada property is located primarily in Enchant, near Vauxhall, Alberta, Canada, at Balsam near Grande Prairie, Alberta, Canada and at Tableland, near Estevan, Saskatchewan, Canada. As of February 27 2012, the Williston Hunter Canada properties included approximately 107,270 gross acres (79,693 net acres). At December 31, 2011, the Williston Hunter Canada prope! rties inc! luded approximately 65 gross productive wells. As of December 31, 2011, Williston Hunter Canada had 41,797 gross (32,944 net) acres of land that is prospective for Bakken and Three Forks/Sanish oil in the Tableland field. The Enchant property consists of 10,720 acres. As of December 31, 2011, 48 wells (44.1 net) were producing on this acreage. As of December 31, 2011, the Company owned approximately 43% average interest in 15 fields located in the Williston Basin in North Dakota consisting of 151 wells, and approximately 15,000 gross (6,450 net) acres.
Appalachian Basin Properties
The properties acquired in the NGAS acquisition are held by its wholly owned subsidiary, Magnum Hunter Production, Inc. As of February 27, 2012, its Appalachian Basin properties included a total of approximately 484,412 gross (412,323 net) acres, located primarily in the Marcellus Shale, Utica Shale and southern Appalachian Basin. At December 31, 2011, proved reserves attributable to its Appalachian Basin properties were 29.9 million barrels of oil equivalent, of which 27% were oil and 59% were classified as proved developed producing, and 30.2 million barrels of oil equivalent. As of February 27, 2012, the Appalachian Basin properties included approximately 3,112 gross (2,257 net) productive wells, of which we operated approximately 88%.
As of February 27, 2012, it had approximately 58,426 net acres in the Marcellus Shale area of West Virginia and Ohio. The Company�� Marcellus Shale property is located principally in Tyler, Pleasants, Doddridge, Wetzel and Lewis Counties, West Virginia and in Washington, Monroe and Noble Counties, Ohio. As of February 27, 2012, the Company operated 33 vertical Marcellus Shale wells and 16 horizontal Marcellus Shale wells. As of February 27, 2012, approximately 63% of its leases in the Marcellus Shale area were held by production.
Other Properties
The Company�� East Chalkley field is located in Cameron Parish, Louisiana.! The fiel! d consists of approximately 714 gross acres (443 net acres). This developmental project is an exploitation of bypassed oil reserves remaining in a natural gas field located at depths between 9,300 and 9,400 feet. As of February 27, 2012, the Company operated the East Chalkley field and owned an approximately 62% working interest and an approximately 42.7% net revenue interest in the field. Other properties of the Company are located in Nacogdoches, Colorado, Lavaca, Bee, Fayette and Wharton Counties, Texas and Desoto Parish, Louisiana. As of February 27, 2012, these properties consisted of an aggregate of approximately 7,050 gross (1,188 net) acres.
Advisors' Opinion: - [By Matt DiLallo]
It's been a tough year for investors of Magnum Hunter Resources (NYSE: MHR ) . As I write this, shares are down about 18% on the year, though shares had been down by more than 37% after the company�announced that it was ditching its auditor. While the stock has slowly recovered, the company has three major action items to accomplish if it wants to win back investors.
